Amoxicillin Articles
FDA panel reviews LYMErix safety
1 February 2001
Ranbaxy antibiotics cleared in USA
7 December 2000
Indian malaria, asthma/ allergy price moves
10 October 2000
Aventis reveals first Phase III Ketek data at ICAAC, sees $1 billion in
28 September 2000
Aventis reveals first Phase III Ketek data at ICAAC
20 September 2000
Ranbaxy forecasting strong growth in 2000
22 May 2000
Sincere Pharma set up in China's Jiangsu
7 December 1999
UK govt inquiry into generics availability
2 November 1999
Bayer gets backing from FDA panel for moxifloxacin
25 October 1999
Third-party payers lead Rx payments
5 May 1999
Pharmacia & Upjohn sells last Spanish plant
23 February 1999
Canadian antibiotic Rxing "down 10%"
26 January 1999
New US CDC otitis media treatment guidelines
26 January 1999
DSM's Acquisition Of Gist-Brocades Was "Good" Move
9 October 1998
Canada Approves Ulcer Combination Therapy
27 August 1998
New Amoxicillin Formulation
22 July 1998
Merck KGaA Expands In Brazil And S Africa
28 May 1998
USA's Most-Dispensed Rx Drugs In April 1998
20 May 1998
EU To Hear Case Against Indian Exports
25 February 1998
Currency Hits SmithKline Beecham Sales And Profits
17 February 1998
Biaxin As Effective As Co-Amoxiclav In Bronchitis
11 February 1998
SB Fears New Generics Prices War In France
8 December 1997
Greek Govt Adjusts Prices Of 6,009 Drugs
3 October 1997
Indian Drug Prices Discussed In Parliament
12 August 1997
First Approval For Glaxo Wellcome's Grepafloxacin
4 August 1997
Strong Sterling Impacts SmithKline Beecham
23 July 1997
Prevacid OK'd For H pylori eradication
26 June 1997
New Data With Glaxo Wellcome's Raxar
9 June 1997
280 Generic Apps Filed In Spain
8 April 1997
Spain Adopts Decree For Introduction Of Generics
24 February 1997
India's Ranbaxy Labs And Crosland Research Merge
10 February 1997
Sanofi Cuts Amoxicillin Price 14% In Generics War
23 December 1996
French Generic Market "Still Weak And Patchy"
16 December 1996
Triple Therapy For H Pylori
28 October 1996
SmithKline Beecham Fights French Generics
14 October 1996
Tactical Diversity In The Evolving US Health Market
17 June 1996
Augmentin Injunction In UK
29 April 1996
Premarin Heads Top-10 Prescription Drugs
1 April 1996
Faes Strengthens Pharma Business
25 March 1996
SB Trading Profit Up 19% On New Prods
26 February 1996
Twice-Daily Augmentin Approved
19 February 1996
Israel's Teva Bidding For World Generics Leadership
12 February 1996
Israeli Survey On OTC Medicines
15 January 1996
Ulcer Therapy Market Set For Transformation
18 December 1995
Effects of Genomics On Antibacterial R&D
20 November 1995
SmithKline Beecham Unveils Power Pipeline
9 October 1995
SmithKline Beecham: new Augmentin data
9 October 1995
Warner-Lambert's cefdinir: new findings
2 October 1995
"Only H pylori And NSAIDs Cause Ulcers"
25 September 1995
Glaxo Wellcome's Pylorid Launched In First Market
18 September 1995
Interest Expenses, Currency Hit SB's Results
31 July 1995
Merck pipline report
3 July 1995
Modern Triple Therapy For H Pylori
8 May 1995
"Strong Underlying Growth" At SB In 1st Qtr
24 April 1995
Spain-Based Fake Drug Business Revealed
13 March 1995
Dae Woong Exports To USA
20 February 1995
$25 Bill Latin American Pharma Market In 2000
9 January 1995
Glaxo Files For Ranitidine Bismuth Citrate Approval
2 January 1995
Helicobacter pylori Eradication Halts Gastric Cancer
28 November 1994
South African Pharma Market $4 Billion In 2002
21 November 1994
Pfizer: Record Number Of Drugs In Phases II & III
31 October 1994
Analysts Upgrade SmithKline Beecham
31 October 1994
1-Hour Treatment For H Pylori?
17 October 1994
SmithKline Beecham On Adapting To Change
10 October 1994
DDT's New Global Pharma Market Review 1994
10 October 1994
Eradication Therapy For Helicobacter Pylori
10 October 1994
BioCraft's Amoxicillin
3 October 1994
Glaxo's Pipeline Update As Expected
19 September 1994
SB Lifts 2nd Qtr Earnings 20%
25 July 1994
ASTA/MERCK AND ABBOTT COLLABORATION
4 July 1994
EUROPE STOCK COMMENT
13 June 1994
GENERIC THREAT TO AUGMENTIN IN UK
6 June 1994
FIRST CLINICAL DATA FOR GLAXO'S GR122311X
6 June 1994
IMPACT OF SWEDISH REFERENCE PRICING PLAN
6 June 1994
EUROPEAN STOCK COMMENT
30 May 1994
SMITHKLINE BEECHAM'S MIXED 1st QTR
2 May 1994
ISRAELI PHARMA MARKET STAGNANT IN 1993
18 April 1994
BIOCRAFT APPROVAL
4 April 1994
ASTRA'S SHARE PRICE TAKES TEMPORARY DIP
4 April 1994
COST-CUTTING IN SPANISH HEALTH CARE
7 March 1994
SMITHKLINE BEECHAM PLEASED WITH RESULTS
28 February 1994
NIH ISSUES CONSENSUS STATEMENT ON H PYLORI
14 February 1994
LIKELY IMPACT ON DRUG FIRMS OF ITALIAN REFORMS
17 January 1994
DRUGMAKERS IN ITALY PANIC ON NEW SALES FEARS
10 January 1994
ASTRA BROADENS RESEARCH BASE
29 November 1993
BRIBERY AND RIVALRY IN PHARMA SECTOR
22 November 1993
WORLD MARKET FOR ANTI-INFECTIVES
15 November 1993
BIAXIN EFFECTIVE FOR OTITIS MEDIA
25 October 1993
DSM ANDENO RELOCATION
23 August 1993
GOOD RESULTS IN 1992 FOR INNOTHERA
12 July 1993
BOOM FORECAST FOR US GENERICS HOUSES
5 July 1993
SMITHKLINE BEECHAM "EXCELLENT PROGRESS"
26 April 1993
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
